Incyte presents Phase 1 data on two cancer drug candidates with high response rates
+1 new source since this summary was written
Incyte disclosed Phase 1 results for its KRAS G12D inhibitor INCB161734 and the bispecific antibody INCA33890 at the ESMO 2026 Congress. The KRAS inhibitor achieved 89% and 69% objective response rates in pancreatic cancer when combined with mFOLFIRINOX and gemcitabine/nab‑paclitaxel, respectively, and a 36% response rate in KRAS‑mutated colorectal cancer with cetuximab. INCA33890 produced a 71% response rate in microsatellite‑stable colorectal cancer when paired with FOLFOX and bevacizumab. The company announced ongoing Phase 3 trials with topline data expected in 2028 and a second‑line colorectal study slated for the first half of 2027.
Why it matters
The data suggest the candidates could become revenue‑generating products if Phase 3 trials confirm efficacy, potentially expanding Incyte’s solid‑tumor portfolio. Investors should watch the 2028 and 2027 Phase 3 read‑outs for material impact on the company’s future cash flow.
Key facts
- 1INCB161734 combined with mFOLFIRINOX yielded an 89% objective response rate in metastatic pancreatic cancer. investing.com
- 2INCB161734 combined with gemcitabine/nab‑paclitaxel yielded a 69% objective response rate in metastatic pancreatic cancer. investing.com
- 3Six‑month progression‑free survival rates were 90% with mFOLFIRINOX and 80% with gemcitabine/nab‑paclitaxel. investing.com
- 4INCB161734 plus cetuximab achieved a 36% objective response rate and 100% disease‑control rate in heavily pretreated KRAS‑G12D colorectal cancer patients. investing.com
- 5INCA33890 combined with FOLFOX and bevacizumab showed a 71% objective response rate and 100% disease‑control rate in microsatellite‑stable colorectal cancer. investing.com
- 6Phase 3 DAWN‑303 trial in first‑line pancreatic cancer has topline data expected in 2028. investing.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.